These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31919792)

  • 1. Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.
    Hilleman DE; Wiggins BS; Bottorff MB
    Adv Ther; 2020 Feb; 37(2):656-670. PubMed ID: 31919792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same.
    Gutstein AS; Copple T
    J Am Assoc Nurse Pract; 2017 Dec; 29(12):791-801. PubMed ID: 29280361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
    Fialkow J
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
    Trivedi K; Le V; Nelson JR
    Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids.
    Brunton S; Collins N
    Curr Med Res Opin; 2007 May; 23(5):1139-45. PubMed ID: 17519081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists.
    Patel D; Busch R
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):524-532. PubMed ID: 34191622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
    Weintraub HS
    Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable.
    Hilleman D; Smer A
    Manag Care; 2016 Jan; 25(1):46-52. PubMed ID: 26882630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
    Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
    Weintraub H
    Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).
    Brinton EA; Mason RP
    Lipids Health Dis; 2017 Jan; 16(1):23. PubMed ID: 28137294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review.
    Balk EM; Adams GP; Langberg V; Halladay C; Chung M; Lin L; Robertson S; Yip A; Steele D; Smith BT; Lau J; Lichtenstein AH; Trikalinos TA
    Evid Rep Technol Assess (Full Rep); 2016 Aug; (223):1-1252. PubMed ID: 30307737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
    Harris WS; Dayspring TD; Moran TJ
    Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
    Reddy KJ; Chowdhury S
    Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea.
    Kim HS; Kim H; Jeong YJ; Yang SJ; Baik SJ; Lee H; Lee SH; Cho JH; Choi IY; Yim HW; Yoon KH
    J Clin Pharm Ther; 2016 Oct; 41(5):508-14. PubMed ID: 27426000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis.
    Quispe R; Alfaddagh A; Kazzi B; Zghyer F; Marvel FA; Blumenthal RS; Sharma G; Martin SS
    Curr Atheroscler Rep; 2022 Jul; 24(7):571-581. PubMed ID: 35499805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.